Sugi Predict

Sugi Predict / Targets / STAMBP

STAMBP

STAM-binding protein · O95630 · STAMBP on Sugi Atlas →

2,790 patent compounds predicted against STAMBP, 1,185 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15660035 SCHEMBL15660035 0.56 17/20
SCHEMBL15661755 SCHEMBL15661755 0.55 17/20
SCHEMBL15658472 SCHEMBL15658472 0.54 17/20
SCHEMBL15659810 SCHEMBL15659810 0.48 17/20
SCHEMBL15961574 SCHEMBL15961574 0.75 16/20
SCHEMBL15660030 SCHEMBL15660030 0.68 16/20
SCHEMBL15660029 SCHEMBL15660029 0.56 16/20
SCHEMBL15661062 SCHEMBL15661062 0.58 15/20
SCHEMBL13977734 SCHEMBL13977734 0.55 15/20
SCHEMBL15659224 SCHEMBL15659224 0.52 14/20
SCHEMBL15660547 SCHEMBL15660547 0.56 13/20
SCHEMBL13978045 SCHEMBL13978045 0.73 12/20
SCHEMBL11499102 SCHEMBL11499102 0.45 9/20
SCHEMBL15660049 SCHEMBL15660049 0.61 8/20
SCHEMBL13978048 SCHEMBL13978048 0.60 8/20
SCHEMBL15660183 SCHEMBL15660183 0.50 7/20
SCHEMBL253871 SCHEMBL253871 0.52 6/20
SCHEMBL15661689 SCHEMBL15661689 0.51 6/20
SCHEMBL15661383 SCHEMBL15661383 0.50 6/20
SCHEMBL255348 SCHEMBL255348 0.49 6/20

Clinical trials — most relevant to STAMBP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Study of Curcumin, Vorinostat, and Sorafenib PHASE1WITHDRAWN
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS PHASE1COMPLETED
Nebulised BromAc in Healthy Volunteers PHASE1COMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs nanCOMPLETED
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Identification of Biomarkers for Early Detection of Pancreatic Cancer nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Molecular Genetics of Retinal Degenerations nanCOMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
Biomarkers in Idiopathic Juvenile Arthritis nanUNKNOWN
Stockholm3 Validation Study in a Multi-Ethnic Cohort nanCOMPLETED
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Congenital Hemolytic and Dyserythropoietic Anemias nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a STAMBP binder may also engage these)

ProteinNameSimilarity
Q8R424 — 0.995 Q8R424 →
Q9CQ26 — 0.991 Q9CQ26 →
Q5R558 — 0.990 Q5R558 →
Q6TH47 — 0.989 Q6TH47 →
Q96FJ0 — 0.988 Q96FJ0 →
Q76N33 — 0.987 Q76N33 →
Q63ZM7 — 0.978 Q63ZM7 →
Q8BMI3 — 0.973 Q8BMI3 →
Q8QFR2 — 0.971 Q8QFR2 →
O12940 — 0.971 O12940 →
O60784 — 0.970 O60784 →
P46737 — 0.970 P46737 →
Q9NVU0 — 0.969 Q9NVU0 →
Q3ZBT2 — 0.969 Q3ZBT2 →
B2RYM5 — 0.969 B2RYM5 →
Q8BPM2 — 0.968 Q8BPM2 →
P70483 — 0.968 P70483 →
Q8BML1 — 0.968 Q8BML1 →
Q9CZT4 — 0.968 Q9CZT4 →
Q80YD1 — 0.968 Q80YD1 →
Q4VA72 — 0.967 Q4VA72 →
O94851 — 0.967 O94851 →
Q80ZD1 — 0.967 Q80ZD1 →
EIF3A Eukaryotic translation initiation factor 3 subunit A 0.967 landscape →
E9Q4Z2 — 0.967 E9Q4Z2 →
Q9UPM8 — 0.967 Q9UPM8 →
Q66GV6 — 0.967 Q66GV6 →
Q80YQ8 — 0.967 Q80YQ8 →
O55091 — 0.967 O55091 →
Q9H8E8 — 0.967 Q9H8E8 →